MXPA03000277A - Inhibidores de metaloproteinasa de matriz. - Google Patents

Inhibidores de metaloproteinasa de matriz.

Info

Publication number
MXPA03000277A
MXPA03000277A MXPA03000277A MXPA03000277A MXPA03000277A MX PA03000277 A MXPA03000277 A MX PA03000277A MX PA03000277 A MXPA03000277 A MX PA03000277A MX PA03000277 A MXPA03000277 A MX PA03000277A MX PA03000277 A MXPA03000277 A MX PA03000277A
Authority
MX
Mexico
Prior art keywords
alkyl
matrix metalloproteinase
metalloproteinase inhibitors
hydrogen
group
Prior art date
Application number
MXPA03000277A
Other languages
English (en)
Inventor
Morten Dahl Soerensen
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of MXPA03000277A publication Critical patent/MXPA03000277A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto de la formula general (I) en donde Y es O o S ; n es 1, 2, 3 o 4; X representa acido hidroxamico, acido carboxilico, acido fosfonico, un grupo acetiltiometilo o un grupo mercaptometilo; R2 representa hidrogeno, alquilo de 1 a 8 atomos de carbono, alquienilo de 2 a 6 atomos de carbono, cicloalquilo de 3 a 8 atomos de carbono, aril-alquilo de 0 a 6 atomos de carbono o heteroaril-alquilo de 0 a 6 atomos de carbono; con la condicion que si A, A¦, Z y R5 son todos enlaces, y s y t ambos son 0 (cero), entonces R6 es diferente de hidrogeno; o una sal, hidrato o solvato del mismo. Los compuestos son valiosos para la terapia humana y veterinaria.
MXPA03000277A 2000-07-18 2001-07-03 Inhibidores de metaloproteinasa de matriz. MXPA03000277A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21903100P 2000-07-18 2000-07-18
PCT/DK2001/000464 WO2002006293A1 (en) 2000-07-18 2001-07-03 Matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
MXPA03000277A true MXPA03000277A (es) 2004-04-05

Family

ID=22817531

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000277A MXPA03000277A (es) 2000-07-18 2001-07-03 Inhibidores de metaloproteinasa de matriz.

Country Status (20)

Country Link
US (1) US6521606B2 (es)
EP (1) EP1303527B1 (es)
JP (1) JP2004504326A (es)
KR (1) KR20030018053A (es)
CN (1) CN1443190A (es)
AT (1) ATE277938T1 (es)
AU (2) AU2001270479B2 (es)
BR (1) BR0112558A (es)
CA (1) CA2416015A1 (es)
DE (1) DE60106048T2 (es)
DK (1) DK1303527T3 (es)
ES (1) ES2228906T3 (es)
HU (1) HUP0302904A3 (es)
IL (1) IL153563A0 (es)
MX (1) MXPA03000277A (es)
PL (1) PL360371A1 (es)
PT (1) PT1303527E (es)
RU (1) RU2270835C2 (es)
SI (1) SI1303527T1 (es)
WO (1) WO2002006293A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
ATE316090T1 (de) * 2002-01-18 2006-02-15 Leo Pharma As Mmp-inhibitoren
WO2004060425A2 (en) * 2002-12-27 2004-07-22 Angiotech International Ag Compositions and methods of using collagen and mmpi
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
BRPI0614262A2 (pt) * 2005-08-02 2011-03-15 Lexicon Pharmaceuticals Inc aril piridinas e métodos para uso das mesmas
CN101679220A (zh) * 2007-04-09 2010-03-24 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732340A (en) * 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
US4618692A (en) * 1981-09-03 1986-10-21 Asta-Werke Aktiengesellschaft 4-carbamoyloxy-oxazaphosphorins
FR2567129B1 (fr) * 1984-07-06 1986-12-05 Adir Nouveaux derives de l'oxaazaphosphorine, leur procede de preparation et les compositions pharmaceutiques les renfermant
PL140732B1 (en) * 1984-07-31 1987-05-30 Polska Akad Nauk Centrum Method of obtaining 2-/2-halogenethylamino/-2-oxo-3-/2-halogenethylo/-1,3,2-oxazophosphorianytes
AU2092597A (en) * 1996-03-07 1997-09-22 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
EP0925303B1 (en) * 1996-08-28 2002-10-23 The Procter & Gamble Company Phosphinic acid amides as matrix metalloprotease inhibitors
US6420586B1 (en) * 2000-08-15 2002-07-16 University Of Kansas Amino acid-derived cyclic phosphonamides and methods of synthesizing the same

Also Published As

Publication number Publication date
HUP0302904A2 (hu) 2003-12-29
IL153563A0 (en) 2003-07-06
CN1443190A (zh) 2003-09-17
SI1303527T1 (en) 2005-04-30
EP1303527A1 (en) 2003-04-23
PT1303527E (pt) 2005-01-31
DE60106048T2 (de) 2006-02-09
AU7047901A (en) 2002-01-30
DK1303527T3 (da) 2005-01-31
RU2270835C2 (ru) 2006-02-27
PL360371A1 (en) 2004-09-06
CA2416015A1 (en) 2002-01-24
EP1303527B1 (en) 2004-09-29
US6521606B2 (en) 2003-02-18
AU2001270479B2 (en) 2005-06-30
DE60106048D1 (de) 2004-11-04
WO2002006293A1 (en) 2002-01-24
HUP0302904A3 (en) 2005-02-28
KR20030018053A (ko) 2003-03-04
JP2004504326A (ja) 2004-02-12
ES2228906T3 (es) 2005-04-16
ATE277938T1 (de) 2004-10-15
US20020103166A1 (en) 2002-08-01
BR0112558A (pt) 2003-07-22

Similar Documents

Publication Publication Date Title
DE69619711D1 (de) Retinoid-potenzierende verbindungen
BRPI0212775B8 (pt) composto de 1,2,4-triazol e medicamento
IS7170A (is) Bensóþíasepín og bensóþíadíasepínafleiður með tálmavirkni gegn dausgarnargallsýruflutningi (ileal bile acid transport, IBAT) til að meðhöndla fitudreyra
NO20032801L (no) Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
ES2054826T3 (es) Peptidos con actividad inhibidora de colagenasa.
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
MXPA03000277A (es) Inhibidores de metaloproteinasa de matriz.
EP1152004A4 (en) PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITOR ACTIVITY
TR200001819T2 (tr) COPD tedavi yöntemi.
EP0656355A4 (en) BIPHENYLMETHANE DERIVATIVE AND MEDICINE CONTAINING THE SAME.
IL162017A0 (en) Mmp inhibitors
YU59401A (sh) Postupak za proizvodnju alendronske kiseline
AU8294401A (en) A process for the preparation of alpha' chloroketones
HU914033D0 (en) Biphosphonic acid derivatives, process for producing said compounds and pharmaceutical preparatives containing them as active substance
NZ337142A (en) Hydroxamic acid compounds
RU94033470A (ru) Циклогексановые производные, фармкомпозиция на их основе и способ лечения
DK1098901T3 (da) Nye 6-deoxyerythromycinderivater, fremgangsmåde til deres fremstilling samt deres anvendelse som lægemidler
MXPA04005839A (es) Nuevos compuestos de benzotiazina y benzotiadiazina un proceso para su preparacion y las composiciones farmaceuticas que los contienen.
DE3366679D1 (en) Substituted heterocyclylphenylsulphonyl and phosphonyl amidines, process for their preparation and their pharmaceutical use
IL160266A0 (en) Hydroxamic acid derivatives
TH55756B (th) สารประกอบอิมิดาโซลที่เป็นเสมือนด้วยยับยั้งฟอสโฟไดเอสเทอเรส vii
HUP0001297A2 (hu) Karbociklussal és heterociklussal helyettesített szemikarbazon- és tioszemikarbazonszármazékok, valamint ezeket tartalmazó gyógyszerkészítmények
TH34907A (th) สารประกอบใหม่

Legal Events

Date Code Title Description
FG Grant or registration